Table 2 Mean ± standard deviation VASI score at each study and follow-up time point compared among the placebo, monotherapy, and combination therapy groups (ITT analysis).

Time point	n	VASI score			p*
Time point	n	Placebo	Bimatoprost 0.01% monotherapy	Bimatoprost 0.01% + NB-UVB	p*
Baseline	19	100.00 ± 0.0	100.00 ± 0.0	100.00 ± 0.0	N/A
1 month	19	100.00 ± 0.0	95.79 ± 8.2	94.74 ± 8.2	0.028^b
2 months	19	98.95 ± 3.2	88.95 ± 13.5	88.95 ± 8.4	0.001^a,b
3 months	19	96.58 ± 6.7	85.00 ± 19.7	77.63 ± 19.9	0.003^b
4 months	19	95.26 ± 11.7	80.26 ± 22.0	64.21 ± 26.8	0.001^b
5 months	19	92.11 ± 17.6	75.00 ± 24.2	60.00 ± 25.4	0.001^b
6 months	19	90.00 ± 21.0	70.00 ± 26.4	55.79 ± 26.8	0.001^b
Follow up at 1 month	19	87.11 ± 23.1	71.05 ± 26.6	55.00 ± 27.9	0.002^b
Follow up at 2 months	19	88.42 ± 23.1	72.37 ± 26.2	55.00 ± 27.9	0.002^b

VASI score Vitiligo Area Scoring Index score, NB-UVB narrowband ultraviolet B phototherapy, ITT intention to treat.
*Repeated measurement ANOVA with multiple comparison by Bonferroni method; statistical significance defined as p-value < 0.05.
^aPlacebo vs monotherapy.
^bPlacebo vs combination therapy.

Quick links

Search